Publication | Closed Access

Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden

ThrombosisVenous ThrombosisHealth EconomicsHealth PolicyOutcomes ResearchVenous Thromboembolism ProphylaxisPharmacoeconomicsPharmacotherapyCost EffectivenessPlatelet AntagonistMedicineAnticoagulant